Loading company…
Riskpilot
← Back to search
Sign in
Get full access
caxpharma AB
AB
Active
Org 5590700471
Övre Långvinkelsgatan 111
Business and other management consultancy activities · NACE 7020
Est. 2016
1 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2025
SEK 1,8M
-19% vs 2024
EBITDA margin
28.4%
-37% vs 2024
Equity ratio
41.3%
Financial strength
Net profit 2025
SEK 306K
-43% vs 2024
EBITDA — year on year
SEK millions
1M
1M
1M
0M
0M
1M
2021
0M
-100%
2022
0M
0%
2023
1M
+100%
2024
0M
-100%
2025
Key figures
Annual report 2025
Revenue
SEK 1,8M
-19%
EBITDA
SEK 496K
-37%
Net profit
SEK 306K
-43%
Total assets
SEK 2M
-6%
Equity
SEK 817K
+1%
Employees
1
—
Company information
Legal name
caxpharma AB
Org number
5590700471
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
13 juli 2016
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Konsultverksamhet inom läkemelsområdet.
Contact
Address
Övre Långvinkelsgatan 111
Email
caxlson@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Business and other management consultancy activities
Companies in Helsingborg
All Sweden companies
Revenue
SEK millions
0M
1M
1M
2M
2M
2M
2021
2M
2022
1M
2023
2M
2024
2M
2025
EBITDA
SEK millions
0M
0M
1M
1M
1M
1M
2021
0M
2022
0M
2023
1M
2024
0M
2025
Income statement
SEK thousands
Item
2021
2022
2023
2024
2025
Revenue
1 722
1 605
1 432
2 169
1 750
Staff expenses
—
−1 012
−1 116
−1 240
−1 112
EBITDA
643
492
206
789
496
Depreciation & amort.
−0
—
—
—
—
EBIT
643
492
206
789
496
Net financials
30
68
1
2
1
Profit before tax
511
436
260
680
390
Tax
−100
−76
−58
−145
−83
Net profit
411
360
202
535
306
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
2025
Total assets
1 700
1 763
1 529
2 097
1 977
Equity
715
674
576
811
817
Long-term debt
0
—
—
—
—
Short-term debt
394
373
291
513
280
Total debt
394
373
291
513
280
Financial ratios
5-year trend
EBITDA margin
28.4%
This company
15.8%
Market median
+80% vs market
2021
2025
Equity ratio
41.3%
This company
38.2%
Market median
+8% vs market
2021
2025
Return on equity
37.5%
This company
18.4%
Market median
+104% vs market
2021
2025
Net profit margin
17.5%
This company
8.1%
Market median
+116% vs market
2021
2025
Asset turnover
0.89×
This company
1.12×
Market median
+21% vs market
2021
2025
Debt / equity
1.42×
This company
0.62×
Market median
-129% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
CE
Carina Elisabeth Axelsson
Board of Directors
2022
MF
Mikael Fredrik Axelsson
Deputy Board Member
2022
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of caxpharma AB also hold positions in
0
other companies.
Person
Role here
Other companies
Carina Elisabeth Axelsson
Board of Directors
0 companies
Mikael Fredrik Axelsson
Deputy Board Member
0 companies